Who we are What we do Steering committee Operating team Trialists Former contributors
Mapping Research delay Treatments tested Networks Research gaps Treatment mapping
Pharmacologic treatments Nonpharmacologic treatments Long COVID treatments Preventive interventions
Living mapping Living evidence synthesis
☰

Vaccines for covid-19 patients

We are currrently developing the protocol for the systematic review on vaccines at the same time we are searching the literature every day and collecting data for candidate vaccines against COVID-19.

Below you can access all the vaccine comparisons where data are available as well as a table with the general characteristics of each trial. For each vaccine comparison, you can access the forest plots for all the outcomes of interest available as well as the Summary of Findings (SoF) table.

We have identified nine vaccine trials so far, data from these trials are under extraction and will be presented on this page.

The evidence synthesis will be added respectively.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Reboot the table and see all comparisons

  • Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Placebo
  • Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp vs Adenovirus type-5-vectored COVID-19 5×10¹° vp
  • Adenovirus type-5-vectored COVID-19 5×10¹° vp vs Placebo

Reboot the table and see all comparisons

Description of primary studies

In this table, we report the main characteristics of the Vaccine RCTs identified.

The link in the column Overall risk of bias will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement. The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column Full description will give you access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.

We are in the process of protocol finalization for vaccine trials with a comprehensive list of outcomes specific to vaccine trials.
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
 Full description
Intervention 1 Intervention 2
NCT04341389
Zhu F, The Lancet, 2020
Full text
Commentary
Commentary
 Mixed Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Placebo RCT Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description

Adenovirus type-5-vectored COVID-19 5×10¹° vp Placebo
Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp Adenovirus type-5-vectored COVID-19 5×10¹° vp